Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HSCT for severe systemic sclerosis and rheumatoid arthritis
ACTRN12611000826943Phase 2Recruiting
- Sponsor
- St. Vincent's University Hospital
- Start
- Aug 2008
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, antithymocyte globulin and filgrastim in systemic sclerosis (SSc) and rheumatoid arthritis (RA), sponsored by St. Vincent's University Hospital. Primary endpoints: Safety and efficacy of HSCT, Health Assessment Questionnaire and 2 more. Started Aug 2008; status: recruiting.
02
Drugs
cyclophosphamideantithymocyte globulinfilgrastim
03
Conditions
systemic sclerosis (SSc)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12611000826943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000826943.